Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXI NASDAQ:EVFM NASDAQ:KRBP NASDAQ:PTIX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.35-0.3%$0.41$0.15▼$0.97$1.16M-0.216,332 shs1,601 shsEVFMEvofem Biosciences$0.01-3.5%$0.01$0.00▼$0.02$1.09M-1.25199,278 shs83,224 shsKRBPKiromic BioPharma$0.16$1.16$0.16▼$3.32$252K1.6611,347 shsN/APTIXAtrinsic$0.50-5.7%$0.62$0.25▼$6.20$905K1.0136,164 shs503 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics+0.97%+21.86%-32.04%+96.33%+35.92%EVFMEvofem Biosciences+6.25%+19.72%+41.67%-4.49%-9.57%KRBPKiromic BioPharma0.00%0.00%0.00%0.00%-23.76%PTIXAtrinsic-5.66%-7.92%-12.27%+18.74%-86.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.35-0.3%$0.41$0.15▼$0.97$1.16M-0.216,332 shs1,601 shsEVFMEvofem Biosciences$0.01-3.5%$0.01$0.00▼$0.02$1.09M-1.25199,278 shs83,224 shsKRBPKiromic BioPharma$0.16$1.16$0.16▼$3.32$252K1.6611,347 shsN/APTIXAtrinsic$0.50-5.7%$0.62$0.25▼$6.20$905K1.0136,164 shs503 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics+0.97%+21.86%-32.04%+96.33%+35.92%EVFMEvofem Biosciences+6.25%+19.72%+41.67%-4.49%-9.57%KRBPKiromic BioPharma0.00%0.00%0.00%0.00%-23.76%PTIXAtrinsic-5.66%-7.92%-12.27%+18.74%-86.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics 0.00N/AN/AN/AEVFMEvofem Biosciences 0.00N/AN/AN/AKRBPKiromic BioPharma 0.00N/AN/AN/APTIXAtrinsic 1.00SellN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/AEVFMEvofem Biosciences$11.39M0.10N/AN/A($2.64) per share0.00KRBPKiromic BioPharmaN/AN/AN/AN/A($8.29) per shareN/APTIXAtrinsicN/AN/AN/AN/A$1.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M-$0.530.02N/AN/AN/A-471.57%-296.50%8/10/2026 (Estimated)EVFMEvofem Biosciences$52.98M-$0.07N/AN/AN/A-46.42%-91.97%-61.93%N/AKRBPKiromic BioPharma-$26.90M-$3.50N/AN/AN/AN/AN/A-277.46%N/APTIXAtrinsic-$5.53M-$3.45N/AN/AN/AN/AN/A-379.72%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/AKRBPKiromic BioPharmaN/AN/AN/AN/AN/APTIXAtrinsicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A2.702.70EVFMEvofem BiosciencesN/A0.110.09KRBPKiromic BioPharmaN/A0.160.22PTIXAtrinsicN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%EVFMEvofem Biosciences0.22%KRBPKiromic BioPharma10.91%PTIXAtrinsic7.97%Insider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics8.60%EVFMEvofem Biosciences0.01%KRBPKiromic BioPharma20.59%PTIXAtrinsic8.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics43.30 million2.02 millionNot OptionableEVFMEvofem Biosciences120132.53 million113.12 millionNot OptionableKRBPKiromic BioPharma601.57 million1.22 millionNot OptionablePTIXAtrinsic21.81 million1.78 millionNot OptionableKRBP, PTIX, ATXI, and EVFM HeadlinesRecent News About These CompaniesAtrinsic (NASDAQ:PTIX) Shares Down 11.6% - Time to Sell?May 27, 2026 | americanbankingnews.comProtagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations PartnerMay 19, 2026 | accessnewswire.comAProtagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114April 23, 2026 | accessnewswire.comAProtagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114March 17, 2026 | accessnewswire.comAAtrinsic (NASDAQ:PTIX) Shares Up 10.9% – Should You Buy?March 4, 2026 | defenseworld.netDResults from Phase 1 Multiple-Dose Study of PT00114December 9, 2025 | accessnewswire.comAProtagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance NoticeNovember 27, 2025 | accessnewswire.comAAtrinsic (NASDAQ:PTIX) Trading Up 2.5% – Time to Buy?November 22, 2025 | defenseworld.netDProtagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD StudyNovember 13, 2025 | accessnewswire.comAProtagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq ComplianceAugust 22, 2025 | accessnewswire.comAProtagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood DisordersAugust 21, 2025 | accessnewswire.comAProtagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug CandidatesJuly 30, 2025 | prismmediawire.comPProtagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug CandidatesJuly 30, 2025 | globenewswire.comProtagenic Therapeutics, Inc. (PTIX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comProtagenic & Phytanix Merge in All-Stock Move, Sparking Retail FrenzyMay 29, 2025 | msn.comProtagenic Therapeutics swaps warrants for sharesMay 21, 2025 | uk.investing.comProtagenic Therapeutics and Phytanix merge in all stock dealMay 21, 2025 | thepharmaletter.comTProtagenic Therapeutics Receives $3.1 Million from Recent Warrant ActivityMay 21, 2025 | accessnewswire.comAProtagenic Therapeutics Shares Double After Buyout Offer From Phytanix BioMay 20, 2025 | marketwatch.comProtagenic Therapeutics stock soars on merger to create Neuroactive Biopharmaceutical companyMay 20, 2025 | in.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKRBP, PTIX, ATXI, and EVFM Company DescriptionsAvenue Therapeutics NASDAQ:ATXI$0.35 0.00 (-0.25%) As of 12:26 PM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Evofem Biosciences NASDAQ:EVFM$0.0082 0.00 (-3.53%) As of 03:57 PM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.Kiromic BioPharma NASDAQ:KRBPKiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.Atrinsic NASDAQ:PTIX$0.50 -0.03 (-5.66%) As of 10:49 AM EasternProtagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
